A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis
The Journal of Allergy and Clinical Immunology, 03/16/2012
Carr W et al. – MP29–02 represents a novel therapy that demonstrated superiority to 2 first–line therapies for allergic rhinitis (AR). Patients with moderate–to–severe seasonal allergic rhinitis (SAR) achieved better control, and their symptoms were controlled earlier with MP29–02 than with recommended medications according to guidelines.